Trials Sponsors Conditions Drugs Pricing

Conditions

Fibrin Blood Clot Pregnancy Pregnancy Complicated by Cardiovascular Disorders as Postpartum Condition, Delivered During Previous Episode

Keywords

fibrinolysisfibrin clotthrombin generation

Outcome Measures

Primary Outcomes (1)

Fibrin clot phenotype
Fibrin clot phenotype
12 months

Study Arms (2)

Healthy pregnant women

Determination of fibrin clot properties and thrombin generation

Diagnostic Test: analysis of fibrin clot properties and thrombin generation

Pregnant women with hypertensive disorders during pregnancy

Determination of fibrin clot properties and thrombin generation

Diagnostic Test: analysis of fibrin clot properties and thrombin generation

Interventions

analysis of fibrin clot properties and thrombin generationDiagnostic test

determination of fibrin clot properties and thrombin generation

Healthy pregnant womenPregnant women with hypertensive disorders during pregnancy

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
analysis of fibrin clot properties and thrombin generation
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age18 Years - 40 Years

Sexfemale(Gender-based eligibility)

Gender Eligibility DetailsFemales as they can get pregnant

Healthy VolunteersYes

Age GroupsAdult (18-64)

Sampling MethodProbability Sample

Study Population

Two groups: 1. Healthy pregnant women 2. Pregnant women with hypertensive disorders during pregnancy

You may qualify if:

Sponsors & Collaborators

Jagiellonian University
Otherlead

Study Sites (1)

Gynecological Endocrinology Department

Krakow, Małopolska, 31-501, Poland

RECRUITING

Magdalena Piróg, MD, PhDCONTACT+48 ext. +48 magda.m.pulka@gmail.com

Biospecimen

Retention: SAMPLES WITHOUT DNA

Venous blood samples will be drawn from an antecubital vein with minimal stasis using atraumatic venipuncture at 8 to 10 AM and collected into serum tubes and into tubes with anticoagulants: EDTAand sodium citrate (2.6 ml and 3.2%, respectively, 9:1) (Monovette, all from Sarstedt, Nümbrecht, Germany).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

November 28, 2025

First Posted

December 10, 2025

Study Start

November 28, 2025

Actual (reported)

Primary Completion

January 2026

Estimated (date passed)

Pregnancy and Fibrin Clot Properties

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Healthy pregnant women

Pregnant women with hypertensive disorders during pregnancy

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Healthy pregnant women

Pregnant women with hypertensive disorders during pregnancy

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations